ミエロペルオキシダーゼ
出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2017/08/19 08:10 UTC 版)
ミエロペルオキシダーゼ(MPO)はペルオキシダーゼに分類される酵素であり、ヒトではMPO遺伝子にコードされている。[5]
| |||||||||||||||||||||
- ^ a b c GRCh38: Ensembl release 89: ENSG00000005381 - Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000009350 - Ensembl, May 2017
- ^ "Human PubMed Reference:".
- ^ "Mouse PubMed Reference:".
- ^ a b “Entrez Gene: Myeloperoxidase”. 2012年1月20日閲覧。
- ^ Klebanoff SJ (May 2005), “Myeloperoxidase: friend and foe”, J. Leukoc. Biol. 77 (5): 598–625, doi:10.1189/jlb.1204697, PMID 15689384
- ^ Mathy-Hartert M, Bourgeois E, Grülke S, Deby-Dupont G, Caudron I, Deby C, Lamy M, Serteyn D (April 1998), “Purification of myeloperoxidase from equine polymorphonuclear leucocytes”, Can. J. Vet. Res. 62 (2): 127–32, PMC 1189459, PMID 9553712
- ^ Heinecke JW, Li W, Francis GA, Goldstein JA (June 1993), “Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins”, J. Clin. Invest. 91 (6): 2866–72, doi:10.1172/JCI116531, PMC 443356, PMID 8390491
- ^ Kettle AJ, Gedye CA, Winterbourn CC (January 1997), “Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide”, Biochem. J., 321 ( Pt 2): 503–8, PMC 1218097, PMID 9020887
- ^ Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A (2000), “Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ?”, Acta Haematol. 104 (1): 10–5, PMID 11111115
- ^ Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL (November 2001), “Association between myeloperoxidase levels and risk of coronary artery disease”, JAMA 286 (17): 2136–42, doi:10.1001/jama.286.17.2136, PMID 11694155
- ^ Nicholls SJ, Hazen SL (June 2005), “Myeloperoxidase and cardiovascular disease”, Arterioscler. Thromb. Vasc. Biol. 25 (6): 1102–11, doi:10.1161/01.ATV.0000163262.83456.6d, PMID 15790935
- ^ Lau D, Baldus S (July 2006), “Myeloperoxidase and its contributory role in inflammatory vascular disease”, Pharmacol. Ther. 111 (1): 16–26, doi:10.1016/j.pharmthera.2005.06.023, PMID 16476484
- ^ Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL (October 2003), “Prognostic value of myeloperoxidase in patients with chest pain”, N. Engl. J. Med. 349 (17): 1595–604, doi:10.1056/NEJMoa035003, PMID 14573731
- ^ Heslop CL, Frohlich JJ, Hill JS (March 2010), “Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography”, J. Am. Coll. Cardiol. 55 (11): 1102–9, doi:10.1016/j.jacc.2009.11.050, PMID 20223364
- ^ Edward G W, Michael JB (April 2001), “Flow cytometry in the diagnosis of acute leukemia”, Seminars in Hematology 38 (2): 124-138, doi:10.1016/S0037-1963(01)90046-0
- ^ Leong A S-Y, Cooper K, Leong, FJ W-M (2003), Manual of Diagnostic Antibodies for Immunohistology, London: Greenwich Medical Media, pp. 325-326, ISBN 1-84110-100-1
- ^ Kagan VE, Konduru NV, Feng W, Allen BL, Conroy J, Volkov Y, Vlasova II, Belikova NA, Yanamala N, Kapralov A, Tyurina YY, Shi J, Kisin ER, Murray AR, Franks J, Stolz D, Gou P, Klein-Seetharaman J, Fadeel B, Star A, Shvedova AA (April 2010), “Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation”, Nat Nanotechnol 5 (5): 354–9, doi:10.1038/nnano.2010.44, PMID 20364135, Lay summary
[続きの解説]
「ミエロペルオキシダーゼ」の続きの解説一覧
- 1 ミエロペルオキシダーゼとは
- 2 ミエロペルオキシダーゼの概要
- 3 構造
- 4 参照
- ミエロペルオキシダーゼのページへのリンク
